Gambaran Umum
Teva Pharmaceutical Industries Limited adalah perusahaan farmasi global yang berkantor pusat di Israel. Berposisi utama di industri obat generik, Teva merupakan salah satu produsen obat generik terbesar di dunia. Perusahaan ini juga mengembangkan, memproduksi, dan memasarkan obat-obatan bermereknya sendiri, yang berfokus pada area terapi seperti gangguan sistem saraf pusat dan masalah pernapasan. Proyek-proyek utama meliputi pengembangan obat generik kompleks, obat khusus, dan produk biofarmasi, dengan komitmen yang signifikan untuk meningkatkan akses terhadap obat-obatan berkualitas tinggi di seluruh dunia. Inisiatif strategis Teva juga berfokus pada penyederhanaan operasi, peningkatan produktivitas R&D, dan pemeliharaan standar kepatuhan yang kuat untuk mendorong pertumbuhan berkelanjutan di tengah kondisi pasar global yang dinamis.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 16,628.00 MM.
- Nilai operating income untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 3,500.00 MM.
- Nilai net income untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -157.00 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 16,628.00 | 3,500.00 | -157.00 |
| 2025-03-31 | 16,616.00 | 3,421.00 | -1,286.00 |
| 2024-12-31 | 16,544.00 | 3,372.00 | -1,639.00 |
| 2024-09-30 | 16,772.00 | 3,730.00 | -959.00 |
| 2024-06-30 | 16,290.00 | 3,485.00 | -453.00 |
| 2024-03-31 | 16,004.00 | 3,341.00 | -478.00 |
| 2023-12-31 | 15,846.00 | 3,180.00 | -559.00 |
| 2023-09-30 | 15,273.00 | 2,568.00 | -2,336.00 |
| 2023-06-30 | 15,017.00 | 2,481.00 | -2,350.00 |
| 2023-03-31 | 14,925.00 | 2,496.00 | -1,711.00 |
| 2022-12-31 | 14,925.00 | 2,662.00 | -2,446.00 |
| 2022-09-30 | 15,141.00 | 2,860.00 | -1,291.00 |
| 2022-06-30 | 15,433.00 | 2,944.00 | -1,054.00 |
| 2022-03-31 | 15,557.00 | 2,995.00 | -615.00 |
| 2021-12-31 | 15,878.00 | 3,079.00 | 417.00 |
| 2021-09-30 | 16,231.00 | 2,964.00 | 726.00 |
| 2021-06-30 | 16,324.00 | 2,911.00 | -3,915.00 |
| 2021-03-31 | 16,284.00 | 2,867.00 | -3,982.00 |
| 2020-12-31 | 16,659.00 | 3,055.00 | -3,990.00 |
| 2020-09-30 | 16,673.00 | 3,033.00 | -4,031.00 |
| 2020-06-30 | |||
| 2020-03-31 |
Laporan Laba Rugi: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | -1.45 | -1.45 |
| 2024-09-30 | -0.85 | -0.86 |
| 2024-06-30 | -0.40 | -0.40 |
| 2024-03-31 | -0.43 | -0.42 |
| 2023-12-31 | -0.50 | -0.50 |
| 2023-09-30 | -2.09 | -2.08 |
| 2023-06-30 | -2.11 | -2.11 |
| 2023-03-31 | -1.54 | -1.54 |
| 2022-12-31 | -2.20 | -2.20 |
| 2022-09-30 | -1.17 | -1.16 |
| 2022-06-30 | -0.95 | -0.95 |
| 2022-03-31 | -0.56 | -0.55 |
| 2021-12-31 | 0.38 | 0.38 |
| 2021-09-30 | 0.66 | 0.66 |
| 2021-06-30 | -3.57 | -3.56 |
| 2021-03-31 | -3.63 | -3.62 |
| 2020-12-31 | -3.64 | -3.64 |
| 2020-09-30 | -3.68 | -3.67 |
| 2020-06-30 | 0.00 | 0.01 |
| 2020-03-31 | -0.76 | -0.75 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 1,390.00 MM.
- Nilai cash from investing activities untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 907.00 MM.
- Nilai kas dari aktivitas pendanaan untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -2,412.00 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | 1,390.00 | 907.00 | -2,412.00 |
| 2025-03-31 | 1,266.00 | 849.00 | -3,384.00 |
| 2024-12-31 | 1,247.00 | 792.00 | -1,791.00 |
| 2024-09-30 | 1,856.00 | 891.00 | -1,693.00 |
| 2024-06-30 | 1,168.00 | 807.00 | -2,269.00 |
| 2024-03-31 | 1,389.00 | 931.00 | -1,358.00 |
| 2023-12-31 | 1,368.00 | 968.00 | -1,913.00 |
| 2023-09-30 | 1,157.00 | 835.00 | -2,048.00 |
| 2023-06-30 | 1,695.00 | 798.00 | -1,912.00 |
| 2023-03-31 | 1,494.00 | 676.00 | -2,195.00 |
| 2022-12-31 | 1,590.00 | 656.00 | -1,487.00 |
| 2022-09-30 | 1,073.00 | 734.00 | -1,277.00 |
| 2022-06-30 | 1,059.00 | 875.00 | -2,014.00 |
| 2022-03-31 | 1,154.00 | 1,176.00 | -1,677.00 |
| 2021-12-31 | 798.00 | 1,523.00 | -2,172.00 |
| 2021-09-30 | 673.00 | 1,418.00 | -1,796.00 |
| 2021-06-30 | 451.00 | 1,287.00 | -1,676.00 |
| 2021-03-31 | 506.00 | 1,119.00 | -1,678.00 |
| 2020-12-31 | 1,216.00 | 863.00 | -1,885.00 |
| 2020-09-30 | 1,423.00 | 1,152.00 | -2,001.00 |
| 2020-06-30 | |||
| 2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 | |||
| 2020-06-30 | |||
| 2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 | ||
| 2020-06-30 | ||
| 2020-03-31 |
Efektivitas Manajemen
- roa untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.03.
- roe untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.02.
- roic untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.05.
- croic untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.05.
- ocroic untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.05.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | -0.03 | -0.02 | -0.05 | -0.05 | 0.05 |
| 2025-03-31 | -0.04 | -0.17 | -0.06 | 0.00 | 0.05 |
| 2024-12-31 | -0.02 | -0.20 | -0.04 | 0.04 | 0.07 |
| 2024-09-30 | -0.01 | -0.13 | -0.02 | -0.02 | 0.05 |
| 2024-06-30 | -0.01 | -0.06 | -0.02 | 0.03 | 0.05 |
| 2024-03-31 | -0.01 | -0.06 | -0.02 | 0.01 | 0.05 |
| 2023-12-31 | -0.05 | -0.23 | -0.08 | -0.00 | 0.04 |
| 2023-09-30 | -0.05 | -0.23 | -0.08 | 0.02 | 0.06 |
| 2023-06-30 | -0.05 | -0.23 | -0.08 | 0.02 | 0.06 |
| 2023-03-31 | -0.03 | -0.16 | -0.05 | -0.00 | 0.05 |
| 2022-12-31 | -0.03 | -0.11 | -0.04 | 0.01 | 0.03 |
| 2022-09-30 | -0.03 | -0.11 | -0.04 | 0.01 | 0.03 |
| 2022-06-30 | -0.02 | -0.09 | -0.03 | -0.01 | 0.03 |
| 2022-03-31 | -0.01 | -0.06 | -0.02 | 0.01 | 0.03 |
| 2021-12-31 | 0.01 | 0.04 | 0.01 | 0.00 | 0.02 |
| 2021-09-30 | 0.01 | 0.07 | 0.02 | 0.01 | 0.02 |
| 2021-06-30 | -0.07 | -0.26 | -0.11 | 0.00 | 0.01 |
| 2021-03-31 | -0.07 | -0.27 | -0.11 | -0.00 | 0.01 |
| 2020-12-31 | -0.07 | -0.26 | -0.11 | 0.01 | 0.03 |
| 2020-09-30 | -0.07 | -0.27 | -0.11 | 0.02 | 0.04 |
| 2020-06-30 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| 2020-03-31 | -0.01 | -0.05 | -0.02 | -0.00 | 0.02 |
Gross Margins
- marjin kotor untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.49.
- marjin bersih untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.08.
- marjin operasi untuk Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.21.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | 0.49 | -0.08 | 0.21 |
| 2025-03-31 | 0.49 | -0.10 | 0.20 |
| 2024-12-31 | 0.49 | -0.06 | 0.22 |
| 2024-09-30 | 0.49 | -0.03 | 0.21 |
| 2024-06-30 | 0.49 | -0.03 | 0.21 |
| 2024-03-31 | 0.50 | -0.04 | 0.18 |
| 2023-12-31 | 0.46 | -0.14 | 0.17 |
| 2023-09-30 | 0.45 | -0.15 | 0.17 |
| 2023-06-30 | 0.45 | -0.15 | 0.17 |
| 2023-03-31 | 0.46 | -0.11 | 0.17 |
| 2022-12-31 | 0.47 | -0.09 | 0.18 |
| 2022-09-30 | 0.47 | -0.09 | 0.18 |
| 2022-06-30 | 0.48 | -0.07 | 0.19 |
| 2022-03-31 | 0.48 | -0.04 | 0.19 |
| 2021-12-31 | 0.48 | 0.03 | 0.19 |
| 2021-09-30 | 0.47 | 0.04 | 0.18 |
| 2021-06-30 | 0.47 | -0.24 | 0.18 |
| 2021-03-31 | 0.46 | -0.24 | 0.18 |
| 2020-12-31 | 0.46 | -0.24 | 0.18 |
| 2020-09-30 | 0.46 | -0.24 | 0.18 |
| 2020-06-30 | 0.45 | 0.00 | 0.18 |
| 2020-03-31 | 0.45 | -0.05 | 0.18 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 818686 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
